Hormonal Disorders

HopeMed advances its androgenetic alopecia treatment to Phase II trials

Hope Medicine has kickstarted recruitment for a Phase II trial assessing  its monoclonal antibody HMI-115 for androgenetic alopecia, after the…

Genexine’s GX-H9 therapy trial meets primary endpoint

Genexine has reported that the Phase III study of eftansomatropin alfa (GX-H9) for the treatment of children with growth hormone…

Xeris Biopharma dosing patients in hypothyroidism drug trial

US-based pharmaceutical company Xeris Biopharma has dosed the first participant in a Phase II clinical trial of subcutaneous (SC) XP-8121…

Extend Biosciences reports positive data from hypoparathyroidism trial

Extend Biosciences has reported positive results from its first-in-human Phase I clinical trial of EXT608 for the treatment of hypoparathyroidism,…

Pipeline Moves: Novartis completes ulcerative colitis trial, advancement prospects rise

This week on Pipeline Moves, we start with the completion of Novartis’s Phase II trial in ulcerative colitis. We also…

DCT Adoption Tracker reveals top therapy areas using a decentralisation approach

Telemedicine remains the leading decentralisation approach in clinical trials in Q2 of this year. The continued rise of telemedicine as…

Pipeline Moves: Phase I/II cystic fibrosis trial of Horizon asset cancelled, shot at further study drops

In this edition of Pipeline Moves, the Clinical Trials Arena team kicks off with an analysis of the termination of…

OPKO Health and Pfizer report positive Phase III data for somatrogon

OPKO Health and Pfizer have reported positive results from the Phase III clinical trial of somatrogon compared to Genotropin (somatropin)…


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.